HARP - Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium | Benzinga
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced abstract acceptance and an upcoming rapid oral presentation of updated interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer (SCLC) and other neuroendocrine tumor types at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) being held in San Francisco, CA and virtually on January 25-27, 2024. HPN328 targets delta-like ligand 3 (DLL3) and is derived from Harpoon's proprietary Tri-specific T cell Activating Construct (TriTAC®) platform designed to recruit a patient's own immune cells to kill tumor cells.
Details of the ASCO-GU presentation are as follows:
Title: "Interim Results from a Phase 1/2 Study of HPN328, a Tri-Specific, Half-Life (T1/2) Extended DLL3-targeting T-Cell Engager in Patients with Neuroendocrine Prostate Cancer (NEPC) and other Neuroendocrine Neoplasms (NEN)"
Abstract number: 121
Session: Rapid Oral Abstract Session A: Prostate Cancer
Session track: Prostate Cancer - Advanced | Prostate Cancer - Localized
Session date & time: Thursday, January 25, 2024 at 4:15 PM – 5:00 PM PST
Presenter: Himisha Beltran, M.D. | Dana-Farber Cancer Institute
Location: Level 3, Ballroom | Livestream
The presentation will also be available on Harpoon's website under Publications following the session.
For more details ...